drugset / Trial / NCT06182774
Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma
Phase 3
Recruiting
570 enrolled
Canadian Cancer Trials Group
Canadian Institutes of Health Research (CIHR) · collabMyeloma Canada · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Currently, daratumumab or isatuximab are given continuously (non-stop), along side lenalidomide, and dexamethasone as part of multiple myeloma treatment. are given continuously (non-stop). Recent observations suggest that stopping daratumumab or isatuximb after about a year and a half of treatment may work just as well as giving them continuously with lenalidomide and dexamethasone. Sometimes, bortezomib is also given. This study is being done to answer the question: is less daratumumab or isatuximab treatment as good as more?
Timeline
- Start
- 2024-04-10
- Primary completion
- 2032-01-31
- Completion
- 2032-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Daratumumab | Monoclonal antibody | — | — |
| Comparator | Isatuximab | Monoclonal antibody | — | — |
| Background | Dexamethasone | Small molecule | — | — |
| Background | Lenalidomide | Other / unclassified | — | — |